ctx130
crispr therapeutics ag
['ctx130', 'crispr']
today at the annual meeting, we presented data on ctx130 in renal cell carcinoma (rcc), as well as preclinical data on the potential of potency-enhanced anti-cd83 car-t cells in preventing relapse in acute myeloid leukemia (aml): #sitc22 